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Abstract
Context: High-amylose sodium carboxymethyl starch (HASCA) was recently proposed as a material for oral,
sustained drug-release tablets prepared by direct compression. It was produced on a pilot scale, but
appeared to be unsuitable for tableting and sustained drug release. Pilot-scale dry powder HASCA was
dispersed in hot water and then precipitated with ethanol to give a dry powder presenting the required
properties, but very high volumes of ethanol were used to recover the product. Objective: A process was
therefore designed to transform totally amorphous pregelatinized HASCA by spray-drying into a suitable
sustained drug-release excipient for matrix tablets while decreasing ethanol quantities. Results and discussion:
During the first manufacturing step, that is, heating of the initial hydro-alcoholic suspension, powder and
water concentrations are key parameters for the acquisition of excellent binding properties. Hence, a
variable ratio of amylose Vh, a crystalline polymorph of amylose, to the amorphous form, is observed
depending on the key parameter values. As the most crystalline samples give the weakest tablets, binding
properties do not appear to be linked to the presence of a Vh form of amylose. On the other hand, a high
water concentration results in excessive tablet strength, that is, inverse conditions leading to the appear-
ance of a Vh form of amylose. Finally, variations in hydro-alcoholic composition appear to affect only
tableting properties and do not influence the drug-release rate. Conclusion: A process designed to trans-
form totally amorphous pregelatinized HASCA by spray-drying is proposed for easier, economical indus-
trial HASCA production.
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Introduction
Starches and modified starches are used currently and
safely in the food and pharmaceutical industries. Various
starch-modification methods, chemical, physical,
enzymatic, or a combination thereof, are employed to
create new starch products with specific or improved
properties. Unmodified and physically modified
starches like totally pregelatinized starch (e.g.,
Lycatab®PGS) or partially pregelatinized starch (e.g., Starch
1500®) have been widely used as binders, disintegrants,
or fillers in tablets1. Starch is considered a good candidate
for chemical reaction/transformation because of its
composition, that is, mixture of amylose and amylopectin,
two glucose polymers presenting three hydroxyl groups
available as chemically active, functional entities.
Oxidation, ethoxylation, and carboxymethylation are
some of the modifications commonly deployed to prepare
starch derivatives. Sodium starch glycolate, a low amylose
content sodium carboxymethyl starch (e.g., Explotab®
or Glycolys®), is a well-known tablet disintegrant2,3.
More recently, Contramid®, a specific type of high-
amylose cross-linked starch, has been used in tablets
for drug-controlled release4.
Substituted amylose (SA) has been introduced as a
promising pharmaceutical excipient for sustained drug
release. SA matrix tablets have been prepared by direct
compression, that is, dry mixing of drug and SA polymers,
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followed by compression, which is the easiest way to
manufacture an oral dosage form5,6. High-amylose corn
starch, containing 70% of amylose chains and 30% of
amylopectin, has been tested for the production of SA
polymers by an etherification process. These polymers
are referred to as SA,R-n, where R defines the substitu-
ent and n represents the degree of substitution (DS)
expressed as the ratio of mole of substituent per kilogram
of amylose5,6. First, a range of substituents, such as
1,2-epoxypropanol (or glycidol=G), 1,2-epoxybutane,
1,2-epoxydodecane, and 1-chlorobutane, were
investigated6. SA,G polymers and especially SA,G-2.7
demonstrated interesting properties as excipients for
controlled drug-release systems. SA,G-2.7 matrices
allowed nearly constant drug release. In vitro dissolution
release times of 95% of the drug ranged from 9 to 20
hours for all DSs studied for 400 mg matrices containing
10% of a soluble drug5,6. Moreover, sustained drug-release
matrix systems based on SA,G technology presented
large ranges for drug-loading, drug solubility, and tablet
weight5,7. Another advantage of this excipient is that
there is no significant influence of compression forces,
ranging from 49 to 490 MPa, on the release properties of
SA,G-n polymers with a DS greater than 1.57. In contrast
to pregelatinized starches known for their poor binding
properties8,9, SA,G polymers have shown good com-
pression behavior, which results in unusually high
crushing strength values comparable to those of micro-
crystalline cellulose tablets, a reference among binders/
fillers5,10. Another striking feature is that, unlike
amylose-based polymers, which are usually subject
to biodegradation by a-amylase enzymes present in the
gastrointestinal tract, SA,G matrix systems and dry-coated
tablets maintain their structure and control [186Re]
release, with no significant degradation by a-amylase11.
Reacting high-amylose starch with sodium chloroace-
tate/chloroacetic acid in place of nonionic substituents
has been proposed for excipients more readily acceptable
by regulatory agencies12,13. Indeed, as mentioned
above, carboxymethyl starch containing low amounts of
amylose already serves as a disintegrating agent in
immediate release tablets. In contrast, high-amylose
sodium carboxymethyl starch (HASCA) has been
recently suggested as a suitable material for oral matrix
tablets12,13. These tablets can be advantageously
improved by the addition of electrolytes as the polymer
is ionic. Such addition permits the integrity of the swollen
matrix tablets to be maintained when they are immersed
in a medium undergoing pH changes simulating the pH
evolution of the environment surrounding an oral pharma-
ceutical dosage form transiting along the gastrointestinal
tract while allowing controlled and sustained drug release
with a remarkably close-to-linear release profile12,13.
The first laboratory-scale batches of nonionic SA
polymers were prepared by reacting the substituent and
high-amylose starch in a heated, alkaline medium. After
neutralization of the suspension, the resultant gel was
filtered and washed with water and acetone. The powder
product was exposed overnight to air, allowing to collect
the excipient in a readily compressible powder form5,12.
HASCA was then produced according to a similar
laboratory-scale process12,13. HASCA was obtained on
a pilot scale using a drying method without organic
solvents. However, the HASCA appeared to be unsuitable
for tableting and sustained drug release. To obtain a dry
powder presenting the required binding and sustained
drug-release properties12,13, the dry powder of pilot-scale
HASCA was thus dispersed in hot water and then
precipitated with ethanol using the laboratory process,
as previously described, though the original process
used acetone to precipitate SA polymers5,6. However,
the main drawback of the above method, that is, precip-
itation by a nonsolvent, is that very high volumes of
organic solvent are needed to recover the product,
yielding 1 part of solid recovered for up to 30 parts or
more of ethanol.
The purpose of our study is to design an original
process transforming totally amorphous HASCA by
spray-drying (SD) into a suitable sustained drug-release
excipient for matrix tablets while decreasing ethanol
quantities and to prepare the scale up for easier and
economical industrial production of HASCA.
Materials and methods
Materials
Amorphous pregelatinized HASCA (batch 3285, ref.
729094) was obtained in powder form from Roquette
Frères (Lestrem, France) and contained approximately
70% of amylose chains and 30% of amylopectin. The DS
was equal to 0.045 (number of moles of substituent/
number of moles of anhydroglucose). Anhydrous etha-
nol was purchased from Commercial Alcohol Inc.
(Brampton, ON, Canada). SA,G-2.7 was obtained
exactly like described in US patent no. 5,879,707.
Acetaminophen was procured from Laboratoires Denis
Giroux Inc. (Ste-Hyacinthe, QC, Canada) and sodium
chloride (NaCl) (crystals, laboratory grade) from
Anachemia Ltd. (Montreal, QC, Canada). All chemicals
were of reagent grade and were used without further
purification.
SD HASCA manufacturing process
Suspensions consisting of amorphous HASCA of
various weights and 80 g of a hydro-alcoholic solution
[containing various % (w/w), water/ethanol] were
heated at 70°C. The solutions were kept at this temperature
for 1 hour under stirring. The solution was then cooled
down to 35°C with stirring. A volume of pure ethanol,
corresponding to a final alcohol to starch ratio of 4 mL:1
g, was added ‘slowly and gradually’ to the solution. The
final suspension was passed through a Büchi B-190
Mini Spray Dryer™ (Büchi, Flawill, Switzerland) at 140°C
to obtain SD HASCA in the form of a fine, dry powder.
The spray-dryer airflow rate was 601 NormLiter/h. The
normalized pump conditions were set at level 4 = 20%,
corresponding to a distilled water flow of 0.35 L/h.
Table 1a and b describes the composition of the
HASCA suspensions during the two operational steps,
that is, heating of the initial hydro-alcoholic suspensions
and SD of the final suspensions: where % (w/w) WATER
= the percent of water by weight in the starting hydro-
alcoholic solution in which the powder is dispersed at the
beginning of the process. Eighty grams of this solution
serves to disperse each HASCA powder sample.
SOLUTION weight (g) = weight of the hydro-alcoholic
solution employed to disperse each HASCA powder
sample.
HASCA weight (g) = weight of the HASCA powder
added to the hydro-alcoholic solution.
% (w/w) HASCA-I = [HASCA weight/(HASCA weight +
SOLUTION weight)] × 100.
% (w/w) water-I = [(water weight)/(HASCA weight +
SOLUTION weight)] × 100.
% (w/w) EtOH-I = [(ethanol weight)/(HASCA weight +
SOLUTION weight)] × 100.
EtOH added (g) = quantity (g) of ethanol added to the
hydro-alcoholic suspension to obtain a SD suspension
having EtOH/HASCA-II ratio of 3.2.
EtOH/HASCA-II = 3.2 = ratio of the total weight of ethanol
on the weight of HASCA in the suspension to be
spray-dried.
% (w/w) HASCA-II = [HASCA weight/(HASCA weight +
SOLUTION weight + EtOH added)] × 100.
% (w/w) water-II = [water weight/(HASCA weight +
SOLUTION weight + EtOH added)] × 100.
% (w/w) EtOH-II = [EtOH total weight/(HASCA weight +
SOLUTION weight + EtOH added)] × 100.
X-ray diffraction
X-ray diffraction (XRD) was performed to characterize
the crystalline or amorphous state of SD HASCA powder
samples. Powder XRD patterns were obtained with an
automatic Philips Diffractometer controlled by an IBM
PC (50 acquisitions, 3–25°q, 1100 points; acquisition
delay 500 ms), using a Cu anticathode (Ka1 1.5405Å)
with a nickel filter. A smoothing function was applied
on the spectra for better reading of the peaks. SA,G-2.7
powder XRD pattern was obtained with an automatic
Inel Diffractometer (Counter CPS120°, 35 kV, 35 mA,
Cobalt wavelength Ka1 = 1.7890Å).
Scanning electron microscopy
The morphology of the samples prepared according to
the manufacturing process described in section ‘SD
HASCA manufacturing process’ was studied by scan-
ning electron microscopy (SEM, Hitachi S 4000, Hitachi,
Tokyo, Japan). Before investigation, the samples were
mounted on double adhesive tape and sputtered with a
thin gold palladium coat.
Table 1. Compositions of (a) HASCA initial hydro-alcoholic suspensions (heating step) and (b) spray-drying suspensions (drying step).
(a) Initial hydro-alcoholic suspensions
Batch % (w/w) WATER SOLUTION weight (g) HASCA weight (g) % (w/w) HASCA-I % (w/w) water-I % (w/w) EtOH-I
A 65.22 80 16 16.67 54.35 28.99
B 65.22 80 12 13.04 56.71 30.25
C 65.22 80 10 11.11 57.97 30.92
D 74.47 80 12 13.04 64.75 22.20
E 74.47 80 10 11.11 66.19 22.70
F 83.33 80 10 11.11 74.07 14.81
G 100.00 80 10 11.11 88.89 0.00
(b) Spray-drying suspensions
Batch EtOH added (g) % (w/w) HASCA-II % (w/w) water-II % (w/w) EtOH-II EtOH/ HASCA-II
A 23.36 13.40 43.71 42.88 3.2
B 10.56 11.70 50.87 37.43 3.2
C  4.16 10.62 55.41 33.97 3.2
D 18.00 10.91 54.12 34.97 3.2
E 11.60  9.84 58.60 31.56 3.2
F 18.64 9.21 61.36 29.43 3.2
G 32.00 8.20 65.57 26.23 3.2
Apparent particle density
Helium pycnometry (Multivolume pycnometer 1305™,
Micromeritics, Norcross, GA, USA) was undertaken.
Powder samples were dried at 100°C in an oven overnight.
The samples were then taken out of the oven and
cooled at ambient temperature in a desiccator and
weighed before measurement. Sample holder volume
was 5 mL, and HASCA sample weight was between 0.5
and 1.5 g. The results are expressed in g/cm3.
Surface area
Krypton adsorption/desorption isotherms were measured
with a Micromeritics ASAP 2010™ instrument
(Micromeritics). HASCA samples were outgassed over-
night at 200°C. Specific surface area was calculated
from adsorption data in the relative pressure range of
0.10–0.28, included in the validity domain of the
Brunauer–Emmett–Teller (BET) equation14. BET-specific
surface area was calculated from the cross-sectional
area of 0.218 nm2 per krypton molecule, following
IUPAC recommendations.
Tablet crushing force
SD HASCA tablets weighing 200 mg were prepared by
direct compression. The excipient was compressed in a
hydraulic press (Workshop Press PRM 8 type, Rassant
Industries, Chartres, France) at a compaction load of
245 MPa with a dwell time of 30 seconds (flat-faced
punch die set). The diameter of all the tablets was 12.6 mm.
Tablet crushing force (Newtons or N) was quantified
with a hardness tester (ERWEKA® Type TBH 200, Erweka
Gmbh, Heusenstamm, Germany). The data presented
here are the mean values of three measurements.
Drug-release evaluation
Matrix tablets were prepared by direct compression. SD
HASCA, acetaminophen, and NaCl were dry-mixed
manually in a mortar. No lubricant was added to the
formulation. Indeed, it was demonstrated earlier that mag-
nesium stearate, at standard levels, did not influence the in
vitro release profile of HASCA matrix tablets containing
NaCl as well as their integrity12,13. Six hundred milligram
tablets, containing 40% of acetaminophen as a model drug,
27.5% of NaCl, and 32.5% of SD HASCA, were produced to
investigate the influence of thermal treatment and SD on
the release characteristics of SD HASCA tablets. They were
prepared in a hydraulic press (Workshop Press PRM 8 type,
Rassant Industries). All tablets were compressed at 245 MPa
for 30 seconds. The diameter of the tablets was 1.26 cm.
The drug-release properties of some typical SD
HASCA matrix tablets were assessed by an in vitro
dissolution test. Because HASCA is an ionic polymer
used for oral, sustained drug release, in vitro release
experiments were conducted in a pH gradient simulating
the pH evolution of the gastrointestinal tract. The tablets
were placed individually in 900 mL of an hydrochloric
acid medium (pH 1.2) simulating gastric pH, at 37°C, in
USP XXIII Dissolution Apparatus No. 2 equipped with a
rotating paddle (50 rpm). They were then transferred to
a phosphate-buffered medium (pH 6.8) simulating
jejunum pH, and finally, transferred to another
phosphate-buffered medium (pH 7.4) simulating ileum
pH, until the end of the test. The dissolution apparatus
and all other experimental conditions remained the
same. The pH gradient conditions were pH 1.2 for 1
hour, pH 6.8 for 3 hours, and pH 7.4 until the end of the
dissolution test (24 hours). The amount of acetami-
nophen released at predetermined time intervals was
followed spectrophotometrically (244 nm). All formula-
tions were tested in triplicate. The drug-release results
are expressed as cumulative percentage in function of
time (hours).
Results and discussion
Process design
Both SA,G-2.7 and HASCA produced at the laboratory
scale demonstrated excellent binding and sustained
drug-release properties5,6,12,13. However, HASCA produced
at the pilot scale did not generate tablets suitable for
sustained drug release.
From the presence of large peaks at 15° and 23.2°
(2q) corresponding to d = 6.5 and 4.4 (Å), it was
concluded that SA,G-2.7 had an essentially amorphous
character with a minor crystalline fraction (Figure 1).
The same was true with laboratory-scale HASCA (data not
shown). The crystalline part of SA,G-2.7 was considered
Figure 1. Powder X-ray diffraction pattern of SA,G-2.7 sample pro-
duced at the laboratory scale.
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as being essentially a V polymorph of amylose. This
polymorph did not occur frequently in cereal starch
compared to other crystalline forms of starch, that is, A
and B polymorphs15. V-amylose, a generic term for
crystalline amylose obtained as single helices, co-crys-
tallizes with compounds such as iodine, fatty acids, and
alcohols16–19. Especially for alcohols, these types of
complexes mainly occur by precipitation of amylose
with alcohols (methanol, ethanol, and n-propanol) in
heated, aqueous solution20–23 or from amylose
solubilized in dimethyl sulfoxide24. This might explain
the presence of amylose–acetone or amylose–ethanol
complexes in SA,G-2.7 or HASCA produced according
to the original laboratory-scale process.
On the other hand, pilot-scale HASCA displays the
characteristic pattern of a totally amorphous powder
(data not shown) and is industrially produced as such
for economical and technical reasons. In light of the
laboratory process5,6, pilot-scale HASCA was dispersed
in hot water and then precipitated with ethanol to
finally collect a dry powder possessing the required
binding and sustained drug-release properties12,13. The
main drawback of this method is that very high volumes
of organic solvent are needed to recover the product,
with yields going to 1 part of solid recovered for up to 30
parts or more of ethanol.
Two main functions of the nonsolvent may be dis-
tinguished: first, precipitation and crystallization of
HASCA, if any, and, second, the removal of residual
water to give a suitable dry powder. The first step is to
dissolve the macromolecules. In the case of amylose,
the macromolecules can be dispersed at a very low
concentration in hot water25–27. Then, the polymer is
precipitated by a nonsolvent addition. The problem
with highly diluted solutions is that they require very
high quantities of nonsolvent to precipitate and
collect a dry powder. Increasing the starch concen-
tration in the solution may solve the problem. How-
ever, because of the presence of its hydroxyl groups,
amylose in aqueous solution forms a gel through
hydrogen-bonding. Thus, raising the starch concen-
tration in water heightens the apparent viscosity of
the solution and the gel formation of starch28. A way
to overcome this problem is to employ an organic
solvent or water/organic solution as medium to limit
the formation of a viscous starch paste29–31. Various
organic liquids like ethyl alcohol32,33 and isopropyl
alcohol29,30,31,34 have been tested. It has been proposed
that alcohol disrupts the amylose gel structure by
bonding to hydroxyl groups on starch molecules.
Unlike water-bonding, this binding is terminal and
produces no connectivity between amylose mole-
cules, reducing the apparent viscosity of the solution
and resulting in amylose precipitation at high alcohol
concentrations28.
Thus, keeping easier, more economical industrial
production of HASCA in mind, an original process was
designed to transform, by SD, amorphous pregelati-
nized HASCA into a suitable sustained drug-release
excipient for matrix tablets, while drastically decreasing
ethanol quantities.
It has been previously observed that (1) XRD results
of laboratory-scale batches, which were used as sustained
release matrices, showed the presence of a minor fraction
of an SA V-form dispersed in a continuous amorphous
phase and (2) pilot-scale HASCA obtained as a pregela-
tinized amorphous powder did not show any binding
or sustained release properties. In view of these obser-
vations, it was first thought that the V-form was necessary
to obtain a suitable, sustained drug-release excipient
(see Figure 1). However, further results surprisingly
showed that in fact this V-form was not necessary to
obtain sustained drug-release properties but even
decreased the binding properties of SD HASCA. Anyway,
a delicate equilibrium had to be maintained between
(a) adequately dispersing and/or dissolving HASCA to
allow crystalline re-arrangement of a fraction of
HASCA shifting from the amorphous state to a V-form,
(b) avoiding a too high increase in viscosity to maintain
acceptable SD conditions, and (c) avoiding unfavorable
HASCA gel formation and/or crystallization occurring
before the SD process as the presence of a carboxylic
function on glucosidic units of HASCA dramatically
influences the gel-forming process through strong
hydrogen-bonding. Furthermore, even if SD appears,
at first glance, to be a practical method to easily remove
large quantities of water from a pharmaceutical prod-
uct, it is not obvious that methods and results, if any,
obtained for native starches and starch derivatives
differing in the nature of their substituents and/or
amylose concentration could be directly applied to the
SD of HASCA. Experiments are thus necessary in case
of processes implying a peculiar thermal treatment and
fast rates of drying, particularly when the amorphous/
crystalline state is of essence in achieving good tablet-
ing and sustained drug-release properties. In fact, the
process described herein is not just a drying process
but more a process to transform an unsuitable product
into an efficient sustained drug-release matrix tablet
excipient.
Thus, in a first step, hydro-alcoholic solutions with
different water/ethanol ratios and HASCA powder
concentrations were prepared. Water concentration
had to remain as low as possible to limit dissolution of
the starch, thus avoiding a too high viscosity hindering
agitation and homogenization. Because, it was first
thought that a crystalline re-arrangement, that is, the
presence of a V-form fraction, was necessary (see Figure 1),
a sufficient amount of ethanol was added to attain
that goal. Then, a volume of ethanol was added after
heating the HASCA suspension. Note that the final
EtOH/HASCA ratio of 3.2 was chosen to limit ethanol
use as much as possible in the process for economical,
environmental, and safety reasons, while still allowing
easy SD. The second step of the process consisted of
recovering the product in the form of a dry powder by
SD. Traditional chemical dehydration by nonsolvent
addition was discarded to avoid the necessity of large
volumes of organic solvent. These working conditions
facilitated the easy production of HASCA powder
samples whose properties are described in subsequent
sections.
X-ray diffraction study
The XRD results on typical SD HASCA samples appear
in Figure 2. The presence of a V-type complex in HASCA
spray-dried batches was verified by XRD. The XRD
diagram of the SD-A sample reveals reflections at Bragg
angles 2θ = 6.80°, 12.96°, 19.92°, and a less intense one
at 2θ = 21.88°. This XRD pattern is close to those
reported previously for pure amylose–ethanol
complexes21. Table 2 reports that such peaks are, in fact,
more characteristic of the Vh amylose polymorph
although the diffraction peaks are broader35. A Vh
amylose structure, often called a pseudo V-form, is
indeed characterized by a larger structure. The V-type
helix is a form of order existing in both crystalline and
amorphous regions36.
A progressive loss of the crystalline part is
observed when decreasing % (w/w) HASCA-I and/or
increasing % (w/w) water-I in the different spray-
dried suspensions (Table 1 and Figure 2). In fact,
usually higher volumes of ethanol are required to
obtain highly crystalline complexes. Here, the crys-
talline part becomes more and more diluted com-
pared to the amorphous part to a point that it is no
longer detectable by XRD. Note that SD-F and SD-G
are not differentiable from SD-E and are not pre-
sented in the figure for the purpose of clarity. SD
samples generate the same type of patterns and thus
the same type of structures, that is, a pseudo V-form
dispersed in an amorphous matrix, although their
respective proportions cannot be determined exactly
here, until of course the pseudo V-form can no more
be detected.
Scanning electron microscopy
An SEM picture of the starting material, that is, amor-
phous pregelatinized HASCA obtained at the pilot level,
appears in Figure 3. The initial product consisted of
large, flat, and splinter-shaped particles.
Products obtained by SD were also characterized by
SEM (Figures 4 and 5). Samples from spray-dried
suspensions were characterized by more or less col-
lapsed spherical particles of various sizes (Figures 4 and 5).
This typical shape appears when, under the drying
action, the solid forms a crust around each droplet,
raising vapor pressure inside. Collapsed particles are
Figure 2. Powder X-ray diffraction patterns of different HASCA sam-
ples produced by spray-drying.
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Table 2. Observed distances (Å) for HASCA and different types of
V-amylose complexes reported in the literature.
Reference
Organic 
solvent Observed d-spacings (Å)
SD-HASCA This work Ethanol 4 4.4 6.8 12.9
SA,G-2.7 This work Acetone 4.4 6.5
Pure V-amylose Bear21 Ethanol 4.5 7
Pure Vh amylose 
Le Bail et al.35
Ethanol 3.93 4.47 6.84 11.87 Figure 3. Scanning electron microscope picture of amorphous
HASCA particles.
created when the vapor is released37. SD-A (Figure 4)
contains large, smooth, and polyhedral particles with
small, more or less collapsed spherical particles often
agglomerated on them. On the other hand, SD-D is
composed of small collapsed spherical particles
together forming larger agglomerates (Figure 5). The
main preparation difference between these two sam-
ples is, on the one hand, the higher % (w/w) HASCA-I
for SD-A, and, on the other hand, the lower % (w/w)
water-I for SD-A compared to SD-D (Table 1). Both fac-
tors do not favor HASCA’s complete dissolution for
SD-A compared to SD-D. In fact, the water/ethanol (p/p)
ratio is approximately equal to 1.9 for SD-A and 2.9 for
SD-D. This could explain the presence of these large
particles in SD-A, most probably corresponding to the
initial amorphous particles that are only partially dis-
solved. Thus, in the case of SD-D, a major part of the ini-
tial starch product is dissolved before being spray-
dried, and the general appearance will be more typical
of a spray-dried product. On the one hand, increasing
water concentration helps to dissolve HASCA, which is
a necessary condition for the formation of a pseudo-V-
amylose complex, because amylose chains have to be
free for that purpose. On the other hand, the SD process
being developed to decrease ethanol concentration will
not lead to amounts of pseudo-V-amylose detectable by
XRD, even if large amounts of amylose are dissolved
previously (Figure 2).
Apparent particle density
The apparent particle density values of samples SD-A
and SD-D are enumerated in Table 3. Apparent particle
density results may be interpreted in light of the infor-
mation garnered by SEM. SD-D had a lower apparent
particle density than SD-A. Indeed, SD-D was
composed of small, more or less collapsed spherical
particles resulting from the SD of HASCA, which had
almost been fully dissolved (Figure 5). It has been
mentioned earlier that, under the drying action, the
solid in the solution formed a crust around each
droplet, raising vapor pressure inside. Eventually,
collapsed particles were formed when the vapor was
released. Such structures were obviously less dense
than plain particles. Indeed, SD-A contained large,
smooth, and polyhedral particles with small, more or
less collapsed spherical particles often agglomerated on
them (Figure 4). These large particles appeared as plain
particles and likely did not present porous structures,
which resulted in increased global apparent particle
density. Also, SD-A had a lower apparent particle
density than amorphous particles. Again, this could
have been related to the bulk aspect of small particles.
Because of surface coagulation and vapor release, SD-A
small particles may have become closed structures with
internal porosity unlike that of amorphous particles. In
fact, amorphous HASCA had a much higher apparent
particle density than all spray-dried samples, which
confirms our interpretation of the apparent particle
density values based on the open or closed porosity of
HASCA particles.
Figure 4. Scanning electron microscope picture of SD-A HASCA
particles.
Figure 5. Scanning electron microscope picture of SD-D HASCA
particles.
Table 3. Apparent particle density values of typical HASCA samples.
HASCA type Apparent particle density (g/cm3)
SD-A 1.26 ± 0.03
SD-D 1.04 ± 0.10
Amorphous starting material 1.48 ± 0.01
Surface area
The specific surface area value of a typical SD sample,
that is, SD-D, has been obtained to gain supplemen-
tary information on the type of product obtained by SD
(S = 2.28 m2/g).
Tablet crushing force
It was not possible to obtain tablets with the initial amor-
phous pregelatinized HASCA pilot batch, even at very high
compression forces (up to 490 MPa). Table 4 gives the
crushing force values of compacts generated by SD
HASCA. Clearly, the SD process produces tablets whose
mechanical properties vary from adequate to excellent.
Some general trends can be underlined concerning
the concentration of the different compounds in the ini-
tial hydro-alcoholic suspension and the SD suspension.
Figures 6–8 depict the influence of various parameters
of the initial hydro-alcoholic and SD suspensions on
tablet crushing force. Figure 6 charts the influence of %
(w/w) HASCA-I of the initial hydro-alcoholic HASCA
suspensions on HASCA tablet crushing force for differ-
ent water concentrations. A quasi-linear relationship
was observed between tablet crushing force and % (w/
w) HASCA-I of the initial hydro-alcoholic solution for
the 11–17% (w/w) range. Interestingly, lower water
concentrations of the starting hydro-alcoholic solution
followed the same trend in parallel but gave higher
tablet crushing force values. We can assume that
decreasing powder weight while keeping the same
water concentration allowed better dissolution of the
initial HASCA dispersion. Considering that the initial
HASCA particles did not show any binding properties,
we may emit the hypothesis that the newly formed
small particles are responsible for the increased crush-
ing force. Indeed, we can suppose that augmenting the
number of smaller particles enlarged the surface area of
the particulate product and, consequently, provided a
higher number of binding points. The progressive dis-
appearance of the large HASCA particles, because of
their progressive dissolution induced by the rising
water/HASCA ratio, thus elicited increased crushing
force. Figure 7 profiles the influence of HASCA
concentration in the SD dispersion [% (w/w) HASCA-II]
on tablet crushing force. The final ethanol addition,
which allowed apparent viscosity reduction of the sus-
pension before SD, did not really change the earlier
observations. Surprisingly, the relationship appeared to
be sigmoid when values obtained for the different water
concentrations were pooled, and a maximum crushing
force value was obtained near 9.5% (p/p) with less
HASCA. Figure 8 enunciates the influence of % (w/w)
WATER of the starting hydro-alcoholic solution on tab-
let crushing force for different weights of HASCA pow-
der dispersed in 80 g of the hydro-alcoholic solution.
Clearly, increasing water concentration in the starting
hydro-alcoholic solution for the same powder quantity
enhanced tablet crushing force until a certain limit was
reached.
Table 4. Tablet crushing force determined for
200 mg tablets (Ø = 12.6 mm, F = 245 MPa) of
pure SD HASCA.
SD HASCA type Mean ± SD (N)
SD-A 60 ± 3
SD-B 107 ± 3
SD-C 142 ± 1
SD-D 143 ± 9
SD-E 170 ± 8
SD-F 182 ± 1
SD-G 186 ± 1
Figure 6. Influence of % (w/w) HASCA-I of initial hydro-alcoholic
HASCA suspensions on HASCA tablet crushing force for different
water concentrations of the starting hydro-alcoholic solution (●:
65.22%, w/w, WATER; : 74.47%, w/w, WATER).
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Figure 7.  Influence of HASCA concentration in spray-drying
solution (%, w/w, HASCA-II) on HASCA tablet crushing force.
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Further, an aqueous HASCA solution was prepared
under the same conditions as for SD-G, but no ethanol
was added before SD. Not only was this solution difficult to
manipulate because of its high viscosity, but also it was
impossible to end the experiment with a laboratory-
scale spray dryer. The high viscosity of this solution
seemed to attract too many problems, confirming the
necessity of the hydro-alcoholic solution in the case of
industrial manufacturing.
Thus, the two key parameters for HASCA excellent
binding properties are powder and water concentrations
during the first manufacturing step, that is, heating of
the initial hydro-alcoholic suspension. A compromise
must be reached between targeting very high tablet
crushing force through a high water concentration and
limiting viscosity through higher alcohol concentration.
In the second stage, the addition of ethanol is more
concerned with decreasing viscosity to easily process
the suspension through the spray dryer than having an
effect on material properties.
Finally, binding properties do not appear to be
linked to the presence of a Vh form of amylose, as the
most crystalline samples are the ones giving the weak-
est tablets (Figure 2 and Table 4). On the other hand,
tablet crushing force rose with water concentration,
although these conditions did not lead to the appear-
ance of a Vh form of amylose. It can be hypothesized
that increasing tablet crushing force was obtained by
first decreasing the particle size of amorphous pregela-
tinized HASCA through SD. Second, the combination of
water and ethanol may have had a plasticizer effect,
helping partial melting of the excipient and particle
re-arrangement under compression. The peculiar
melting process was demonstrated earlier by SEM and
porosimetry in the case of SA,G-2.7, although no expla-
nation was provided5,10.
Drug-release evaluation
Typical drug-release profiles from matrix tablets made
of spray-dried HASCA are shown in Figure 9. SD-A,
SD-D, and SD-F were chosen because they present
different crystalline levels and different binding proper-
ties. Acetaminophen release was found to be similar for
the three samples. The time for 95% drug release was
equal to 16:30 hours, and it could be said that SD
HASCA matrix systems exhibited sustained drug-
release properties. Thus, combined with the heating of
HASCA hydro-alcoholic suspensions, the SD process
was able to restore binding and sustained drug-release
properties. Further, it appears that, within the limits of
this protocol, variations in hydro-alcoholic composition
only affected tableting properties and did not influence
the drug-release rate. The presence of the Vh form of
HASCA appears to be unnecessary to obtain sustained
drug release (Figures 2 and 9), but also its concentration
does not influence the drug-release process, provided it
remains as a minor component in the amorphous
matrix. This is certainly an advantage as it makes the
method robust and allows us to focus on the experi-
mental conditions of heating HASCA hydro-alcoholic
suspensions to optimize tablet strength in the design of
an industrial manufacturing process.
Conclusion
Pregelatinized amorphous HASCA produced on a
pilot scale appeared to be unsuitable for tableting
and sustained drug release. The main drawback of the
laboratory process, precipitation by a nonsolvent, was
that very high volumes of ethanol were used to recover
the product with yields going to 1 part of solid recovered
Figure 8. Influence of % (w/w) WATER of the starting hydro-alco-
holic solution on HASCA tablet crushing force for different weights
of HASCA powder dispersed in 80 g of hydro-alcoholic solution
(: 12 g HASCA; ♦: 10 g HASCA).
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Figure 9. Cumulative percentage of acetaminophen released in
vitro from optimized HASCA matrices (32.5% of HASCA, 40% of ace-
taminophen, and 27.5% of NaCl) in standard pH gradient condi-
tions (▲: SD-A; ❍: SD-D; : SD-F).
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for up to 30 parts and more of ethanol. An original process
was designed to transform totally amorphous
pregelatinized HASCA by SD into a suitable sustained
drug-release excipient for matrix tablets while decreasing
ethanol quantities and to prepare the scale up for easier
and economical industrial production of HASCA. This
process involves a final EtOH/HASCA ratio of 3.2, which
is an advantage for economical, environmental, and
safety reasons. The two key parameters for obtaining
excellent SD HASCA-binding properties are powder
and water concentrations during the first manufacturing
step, that is, heating of the initial hydro-alcoholic
suspension. A compromise must be reached between
targeting very high tablet crushing force through high
water concentration and limiting viscosity through
higher alcohol concentration. In the second stage, the
addition of ethanol before SD is more concerned with
decreasing viscosity to easily process the suspension
through the spray dryer than having an effect on
material properties. Binding properties do not appear
to be linked to the presence of a Vh form of amylose, as
the most crystalline samples are the ones giving the
weakest tablets. On the other hand, high water concen-
tration leads to high tablet crushing force, that is, inverse
conditions evoking the appearance of a Vh form of
amylose. We hypothesize that increasing tablet crush-
ing force is possible by first decreasing the particle size of
amorphous HASCA through SD. Second, the combination
of water and ethanol may have a plasticizer effect, helping
partial melting of the excipient and particle re-arrangement
under compression. Finally, it appears that variations in
hydro-alcoholic composition affect only tableting
properties and do not influence the drug-release rate.
The presence of the Vh form of HASCA appears to be
unnecessary to obtain sustained drug release, but also
its concentration does not influence the drug-release
process, provided it remains as a minor component in
the amorphous matrix. This is certainly an advantage,
making the method robust and focusing on the experi-
mental conditions of heating HASCA hydro-alcoholic
suspensions, to optimize tablet strength in the design of
an industrial manufacturing process.
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